Recombinant Human Vitronectin Protein (N-Truncated, C-6His)

Beta LifeScience SKU/CAT #: BL-2319NP
BL-2319NP: Greater than 90% as determined by reducing SDS-PAGE. (QC verified)
BL-2319NP: Greater than 90% as determined by reducing SDS-PAGE. (QC verified)

Recombinant Human Vitronectin Protein (N-Truncated, C-6His)

Beta LifeScience SKU/CAT #: BL-2319NP
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Vitronectin is produced by our Mammalian expression system and the target gene encoding Val62-Leu478 is expressed with a 6His tag at the C-terminus.
Accession AAH05046.1
Synonym Complement S-protein; epibolin; Serum Spreading Factor; Serum-spreading factor; Somatomedin B; S-protein; V75; Vitronectin; VN; VNT; VTN
Gene Background Vitronectin, also known as VTN, is a large glycoprotein found in blood and the extracellular matrix (ECM). Vitronectin is a plasma glycoprotein implicated as a regulator of diverse physiological process, including blood coagulation, fibrinolysis, pericellular proteolysis, complement dependent immune responses, and cell attachment and spreading. Blocking of Hic(a member of the pneumococcal surface protein C (PspC) family) by specific antiserum or genetic deletion significantly reduced pneumococcal binding to soluble and immobilised vitronectin and to Factor H, respectively. In addition, Vitronectin interact with glycosaminoglycans and proteoglycans. Is recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway.
Molecular Mass 48.3 KDa
Apmol Mass 60-70 KDa, reducing conditions
Formulation Lyophilized from a 0.2 μm filtered solution of 20mM Tris HCl, 150mM NaCl, 0.02% Tween 80, pH8.0.
Endotoxin Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity Greater than 90% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Not tested
Reconstitution Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

Target Details

Target Function Vitronectin is a cell adhesion and spreading factor found in serum and tissues. Vitronectin interact with glycosaminoglycans and proteoglycans. Is recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway.; Somatomedin-B is a growth hormone-dependent serum factor with protease-inhibiting activity.
Subcellular Location Secreted, extracellular space.; Parasitophorous vacuole.
Database References
Tissue Specificity Expressed in the retina pigment epithelium (at protein level). Expressed in plasma (at protein level). Expressed in serum (at protein level).

Gene Functions References

  1. Insulin resistance and age independently predicted VTN levels. VTN may be a candidate target for the appraisal of hepatic insulin resistance in patients with type 2 diabetes. PMID: 29780059
  2. The 10 kDa C-terminal fragment of the ECM protein vitronectin (VTN) was then selected as a promising circulating biomarker in discriminating Nonalcoholic steatohepatitis. PMID: 29463024
  3. The authors observed that exposure of Burkholderia pseudomallei and the closely related yet avirulent Burkholderia thailandensis to human plasma increased epithelial cell invasion by >20 fold. Receptor blocking studies with RGD-domain containing peptide and alphaV beta3 blocking antibody identified complement-activated vitronectin as the factor facilitating this invasion. PMID: 28186697
  4. Additionally, the authors utilized vitroenctin-derived peptides to map the minimal Rickettsia conorii Adr1/human vitronectin interaction to the C-terminal region of vitronectin. PMID: 28299286
  5. We show that small N-terminal fragments of VN consistent with processing of the RGD motif are present in liquid biopsies of cancer patients as well as in the urine of healthy individuals. PMID: 27189837
  6. Serum vitronectin levels are elevated in human glioma, as well as are independently associated with pathologic grade based on WHO classification and 5-year poor prognosis. Moreover, this biomarker significantly discriminates gliomas from controls, other non-glioma brain tumors and other non-tumor neurological diseases, distinguishes high-grade gliomas from low-grade gliomas, and predicts 5-year progression and mortality. PMID: 27871448
  7. Elevated serum VN levels represented high diagnostic value and had close relation to clinicopathological factors and early recurrence, suggesting that serum VN might be a useful diagnostic and prognostic marker for HCC. PMID: 27802203
  8. We confirmed increased levels of C1R and VTN in sera from patients with Joint hypermobility syndrome by western blot analyses PMID: 26709396
  9. This study examines the complexes of PAI-1 with tissue-type and urokinase-type plasminogen activator and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop. PMID: 26548921
  10. Ail-expressing Yersinia pestis strains bind vitronectin - a host protein with functions in cell attachment, fibrinolysis and inhibition of the complement system. PMID: 26377177
  11. High expression of VN in tumor cells independently indicated poor clinical prognosis in patients with osteosarcoma. PMID: 26617861
  12. The mean level of PAI-1 was 23.02 +/- 15 (8.2-71.19) ng/mL and vitronectin was 83.10% +/- 23.77% (12%-126%) in the tumor group. PMID: 24770328
  13. Bacterial protein-E and host vitronectin play a role in the attachment to bronchial epithelial cells and is also involved in the subsequent intracellular invasion of nontypeable Haemophilus influenzae. PMID: 26572616
  14. P. aeruginosa isolates obtained from CF patients significantly bound vitronectin. Porin D was defined as a novel P. aeruginosa vitronectin-receptor PMID: 26047937
  15. Lpd of P. aeruginosa is a surface exposed moonlighting protein that binds two human terminal pathway inhibitors, vitronectin and clusterin PMID: 26368530
  16. The VN level may be relevant as a clinical biomarker for adverse cardiovascular outcomes not only in patients with ischemic heart disease undergoing coronary interventions. PMID: 24823429
  17. Vitronectin expression in the airways of subjects with asthma and chronic obstructive pulmonary disease PMID: 25768308
  18. Gpm1 in Candida albicans attaches to human endothelial cells and to keratinocytes via the adhesive protein vitronectin PMID: 24625558
  19. Vitronectin is identified as a common constituent of amyloid deposits in 175 formalin-fixed and paraffin-embedded tissue samples from a large variety of different amyloid diseases. PMID: 26101327
  20. Hic interacts with vitronectin and simultaneously with Factor H, and both human proteins may contribute to colonisation and invasive disease caused by serotype 3 pneumococci. PMID: 25181963
  21. VTN plays a significant role in the malignant growth of tumor. PMID: 25179307
  22. Melanoma cell adhesion to vitronectin is dependent on beta-1,6-branched N-glycans. PMID: 24687613
  23. A total of 17 site-specific N-glycopeptides were completely identified in all of the three N-glycosylation sites of vitronectin in human plasma, including 12 N-glycopeptides first reported. PMID: 25374123
  24. The presence of VN on the material surfaces enhanced cell-mediated FN reorganization and secretion. PMID: 23899674
  25. serum levels of both fibronectin and vitronectin may be the diagnostic markers in melanoma patients, but not markers of prognosis PMID: 24999757
  26. Authors demonstrate that an evolutionarily conserved rickettsial antigen, Adr1/RC1281, interacts with human vitronectin and is sufficient to mediate resistance to serum killing when expressed at the outer-membrane. PMID: 24286496
  27. The interaction between uPAR and vitronectin triggers ligand-independent adhesion signalling by integrins. PMID: 25168639
  28. A strong linkage disequilibrium was found in vitronectin promoter in Chinese with vascular disease. PMID: 23041018
  29. Vn competes with hTSP-1 for binding to Atl repeats and vice versa. In conclusion, this study identifies the Atl repeats as bacterial adhesive structures interacting with the human glycoproteins hTSP-1 and Vn. PMID: 24371140
  30. increased expression levels of VN protein and mRNA in placental maternal-fetal interface of EOSP may be involved in adhesion and repair of placental infarct lesions. PMID: 23124223
  31. Interaction of vitronectin with integrin alphavbeta3 results in the continued activation of the kinase mTOR. PMID: 23722547
  32. In conclusion, the head domains of UspA2/2H have extensive sequence polymorphism without losing vitronectin-binding capacity promoting a general evasion of the host immune system. PMID: 23474333
  33. study highlights that ascites-derived fibronectin and vitronectin exhibit different properties depending on the ascites PMID: 23811340
  34. An isogenic nontypeable Haemophilus influenzae 3655Deltahpf mutant devoid of protein F displayed a reduced binding of vitronectin, and was consequently more sensitive to killing by human serum compared with the wild type. PMID: 23387957
  35. The choline-binding protein PspC of Streptococcus pneumoniae interacts with the C-terminal heparin-binding domain of vitronectin. PMID: 23603906
  36. Importance of vitronectin and its interaction with the urokinase receptor in tumor growth. PMID: 23327926
  37. There was no difference in serum vitronectin levels between Behcet's disease patients and control subjects, and there was no statistically significant difference between vitronectin levels in Behcet patients with and without ocular involvement. PMID: 22810367
  38. In this study, the authors demonstrate meningococcal interactions with vitronectin via a novel adhesin, Msf (meningococcal surface fibril, previously NhhA or Hsf). PMID: 22050461
  39. higgh plasms levels is associated with the risk of metabolic syndrome and type 2 diabetes mellitus PMID: 21800006
  40. A series of truncated vitronectin molecules revealed that the C-terminal domain comprising vitronectin(353-363) harboured the major binding region for Haemophilus influenzae protein E. PMID: 21542857
  41. High serum vitronectin is associated with breast cancer. PMID: 21253761
  42. PAI-2 is capable of inhibiting uPA in the presence of PAI-1, particularly on adherent cells in the presence of vitronectin PMID: 21316840
  43. Thrombospondin 1, fibronectin, and vitronectin are differentially dependent upon RAS, ERK1/2, and p38 for induction of vascular smooth muscle cell chemotaxis. PMID: 21193465
  44. The results provide the first evidence for vitronectin gene expression in urothelial cells. PMID: 21048021
  45. Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices PMID: 20492459
  46. expression of vitronectin at the periphery of mesothelial cells and within ovarian cancer cell clusters suggests a potential role for this molecule during intraperitoneal implantation of ovarian cancer cells PMID: 20121701
  47. This study directly reveals the binding mode between the N-terminal domain of UspA2 Moraxella catarrhalis and the C-terminal part of vitronectin and thus sheds light upon the mechanism of Moraxella catarrhalis-dependent serum resistance. PMID: 20199596
  48. Data reveal that multimeric VTNC attenuate Cyr61 binding to immobilized VTNC, while monomeric VTNC was ineffective. PMID: 20195466
  49. A fragment of vitronectin containing the RGD integrin binding site showed similar binding affinity as that of full vitronectin protein to purified integrin alphavbeta3 but had diminished cell adhesion and spreading function in vivo. PMID: 20600001
  50. Neisseria meningitidis Opc expressed in acapsulate as well as capsulate bacteria can increase human brain endothelial cell line adhesion and entry by first binding to serum vitronectin PMID: 20502634


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed